Catalent Inc. completed the tender offer to acquire all outstanding shares of Juniper Pharmaceuticals Inc. for $11.50 apiece.

A total of 9,285,239 common shares, representing about 82% of Juniper's outstanding common shares, were validly tendered and not withdrawn at midnight ET on Aug. 13, the offer's expiration date.

Catalent said it expects to close the merger Aug. 14. All remaining shares will be converted into a right to receive $11.50 in cash per share upon the deal's closing.

Following merger completion, Juniper will be a wholly owned unit of Catalent and its common shares will be delisted from the Nasdaq Global Select Market.